Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CEL-SCI Corp CVM

Healthcare Biotechnology
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.


NYSEAM:CVM - Post by User

CEL-SCI Corp
Bullboard Posts
User Avatar Image
(0)
•••
Post by delaneon Nov 06, 2012 11:22am
231 Views
Post# 20567350

Cel-Sci Corporati Went the additional Mile! Cel-Sc

Cel-Sci Corporati Went the additional Mile! Cel-Sc

Volume, 142650, came torrential in today as the average volume is at 730679. Very typical activity at this point which I knew that Cel-Sci Corporati would rally when I erudite about caption news about a month ago. Even if I didn't get in on CVM it's looking onward to a nice short rally. The basics of Cel-Sci Corporati llook huge and analyst place the 1 year target price at .

https://stocktradingeasy.com/

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities